Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. lifted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 23.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,439,740 shares of the biopharmaceutical company's stock after acquiring an additional 269,733 shares during the quarter. Alyeska Investment Group L.P. owned 1.56% of Ultragenyx Pharmaceutical worth $60,570,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Van ECK Associates Corp grew its holdings in Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after buying an additional 294 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares during the last quarter. Arizona State Retirement System increased its holdings in Ultragenyx Pharmaceutical by 2.4% during the 4th quarter. Arizona State Retirement System now owns 24,038 shares of the biopharmaceutical company's stock valued at $1,011,000 after acquiring an additional 568 shares in the last quarter. Finally, Guggenheim Capital LLC raised its position in Ultragenyx Pharmaceutical by 1.5% during the fourth quarter. Guggenheim Capital LLC now owns 45,222 shares of the biopharmaceutical company's stock worth $1,902,000 after acquiring an additional 670 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on RARE. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Piper Sandler reduced their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. JPMorgan Chase & Co. lifted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. HC Wainwright restated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Finally, Wedbush reiterated a "neutral" rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $92.79.

Insiders Place Their Bets

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the transaction, the executive vice president now directly owns 54,991 shares in the company, valued at $2,358,014.08. This represents a 5.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John Richard Pinion sold 14,439 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the completion of the sale, the insider now owns 107,766 shares in the company, valued at $4,536,948.60. The trade was a 11.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 125,405 shares of company stock valued at $5,285,169 over the last 90 days. 5.50% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Stock Down 4.7 %

Shares of Ultragenyx Pharmaceutical stock traded down $1.64 during trading hours on Wednesday, hitting $33.42. 1,766,624 shares of the company's stock traded hands, compared to its average volume of 817,524. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37. The company has a market cap of $3.14 billion, a PE ratio of -5.27 and a beta of 0.34. The stock has a 50 day simple moving average of $37.18 and a 200-day simple moving average of $42.74.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business's revenue for the quarter was up 28.0% on a year-over-year basis. During the same period in the previous year, the company earned ($2.03) earnings per share. As a group, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.